Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 24 Jan 2022
TGA approves MSD's Vaxneuvance
24 January 2022 - Vaxneuvance (pneumococcal 15 valent conjugate vaccine (CRM197 protein)) was approved on 17 January 2022 for active ...
Posted by Michael Wonder on 24 Jan 2022
Novavax COVID-19 vaccine to be available in coming weeks
24 January 2022 - Australians aged 18+ will now have access to a fourth COVID-19 vaccine, Nuvaxovid (Novavax) in coming weeks, ...
Posted by Michael Wonder on 24 Jan 2022
FDA considers limiting authorisation of certain monoclonal antibody treatments
23 January 2022 - Federal regulators are considering limiting the authorisation of certain monoclonal antibody treatments that have not proved ...
Posted by Michael Wonder on 24 Jan 2022
Patients to receive new cancer drugs faster under Brexit rules shake-up
23 January 2022 - Seven medicines already approved as changes cut as much as a month off approval times. ...
Posted by Michael Wonder on 24 Jan 2022
Australians with severe dermatitis to benefit from PBS listing
24 January 2022 - From 1 February 2022, Australians with severe atopic dermatitis will have access to a new treatment ...
Posted by Michael Wonder on 23 Jan 2022
ATAGI statement on the use of Novavax COVID-19 vaccine (Nuvaxovid)
24 January 2022 - ATAGI recommends that Novavax COVID-19 vaccine can be used for the primary course of COVID-19 vaccination ...
Posted by Michael Wonder on 23 Jan 2022
Pharmacists struggle to meet demand for free COVID test kits amid stock shortage
23 January 2022 - Chemists across the country say they do not have enough rapid antigen tests to start handing ...
Posted by Michael Wonder on 23 Jan 2022
Thousands to benefit from decision to subsidise eczema treatment
23 January 2022 - Australians suffering from a severe form of eczema will save tens of thousands of dollars after a ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19: early access granted to Paxlovid as a curative treatment
21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19 vaccines and treatments: we must have raw data, now
19 January 2022 - Data should be fully and immediately available for public scrutiny ...
Posted by Michael Wonder on 22 Jan 2022
Patent thickets are thwarting U.S. availability of lower cost biosimilar medicines, study finds
18 January 2022 - Amid debate over competition in the pharmaceutical industry, a new analysis found just 6% of patents ...
Posted by Michael Wonder on 22 Jan 2022
FDA takes actions to expand use of treatment for outpatients with mild to moderate COVID-19
21 January 2022 - Today, the U.S. FDA took two actions to expand the use of the antiviral drug Veklury (remdesivir) ...
Posted by Michael Wonder on 21 Jan 2022
Pfizer and OPKO provide update on the biologics license application for somatrogon for paediatric growth hormone deficiency
21 January 2022 - Pfizer and OPKO Health announced today that the U.S. FDA issued a complete response letter for the ...
Posted by Michael Wonder on 21 Jan 2022
International regulators’ recommendations on COVID-19 vaccines and the Omicron variant
21 January 2022 - International regulators have published a report today highlighting their discussions on the effectiveness of current vaccines against ...
Posted by Michael Wonder on 21 Jan 2022
U.S. FDA approves second indication for Skyrizi (risankizumab-rzaa) to treat adults with active psoriatic arthritis
21 January 2022 - Skyrizi (risankizumab-rzaa) met the primary endpoint of ACR20 at week 24 in two pivotal studies, demonstrating significant ...